Abraxane

Abraxane

Emerging Trends in Nanotechnology for Diagnosis and Therapy of Lung Cancer

Published in Alok Dhawan, Sanjay Singh, Ashutosh Kumar, Rishi Shanker, Nanobiotechnology, 2018

Nanda Rohra, Manish Gore, Sathish Dyawanapelly, Mahesh Tambe, Ankit Gautam, Meghna Suvarna, Ratnesh Jain, Prajakta Dandekar

In the United States, Abraxane® was first approved in January 2005 for the treatment of breast cancer, after failure of combination chemotherapy or remission within 6 months of adjuvant chemotherapy for the metastatic disease. It has been globally approved for the treatment of metastatic breast cancer (MBC) in more than 40 countries. In October 2012, Abraxane® was approved by the FDA as the first-line therapy for locally advanced or metastatic NSCLC, in combination with carboplatin, in patients who cannot undergo curative surgery or radiation therapy. An overview of approval proceedings followed for Abraxane® by FDA is given in Table 4.10.

Nano-dimensional gold synthesis for biomedical applications: upscaling and challenges

View Article

Journal Information

Published in Particulate Science and Technology, 2023

Subhasis Chakraborty, Suvadeep Mal, Asim Halder, Suvadra Das, Kalyan Kumar Sen, Arup Mukherjee, Partha Roy

There are some established nanodimensional products that has entered in the market for the management of clinical disorders. Doxil for treatment of ovarian cancer (Lehner et al. 2013) and Abraxane for treatment of breast cancer (Kharlamov and Gabinsky 2012) are some of the representatives of this group. Some nano-gold products are also approved for commercialization by USFDA (Zeng et al. 2013) (Table 4).

Explore chapters and articles related to this topic

Emerging Trends in Nanotechnology for Diagnosis and Therapy of Lung Cancer

Nano-dimensional gold synthesis for biomedical applications: upscaling and challenges